Retatrutide
Triple agonist (GLP-1 / GIP / Glucagon) — investigational metabolic peptide.
Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP and glucagon receptors. In research it has demonstrated some of the largest weight-reduction effects reported for any incretin-class molecule, alongside improvements in glycemic control and hepatic fat.
Reported benefits
- Pronounced reductions in body weight in trial subjects
- Improved insulin sensitivity and fasting glucose
- Reduced hepatic steatosis markers
- Appetite suppression and slower gastric emptying
Reported drawbacks
- GI side effects: nausea, vomiting, constipation, diarrhea
- Possible elevated heart rate
- Rapid loss of lean mass if calories/protein too low
- Long half-life — side effects can linger
Available: Retatrutide 10mg · Retatrutide 15mg · Retatrutide 20mg · Retatrutide 30mg